

Guidelines on the diagnosis and management of multip

British Journal of Haematology

132, 410-451

DOI: [10.1111/j.1365-2141.2005.05867.x](https://doi.org/10.1111/j.1365-2141.2005.05867.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Bisphosphonates and phossy-jaw: breathing new life into an old problem. <i>Lancet Oncology</i> , The, 2006, 7, 447-449.	10.7	17
3	Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function. <i>Clinical Therapeutics</i> , 2006, 28, 953-959.	2.5	18
4	Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. <i>Blood</i> , 2006, 108, 2013-2019.	1.4	88
5	The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British society of blood and marrow transplantation study. <i>British Journal of Haematology</i> , 2006, 134, 385-390.	2.5	55
6	Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. <i>British Journal of Haematology</i> , 2006, 134, 620-623.	2.5	258
7	Hyperbaric Oxygen in Addition to Antibiotic Therapy Is Effective for Bisphosphonate-Induced Osteonecrosis of the Jaw in a Patient with Multiple Myeloma. <i>International Journal of Hematology</i> , 2006, 84, 343-345.	1.6	33
8	Multiple Myeloma Early Recognition by Primary Care Nurse Practitioners. <i>Journal for Nurse Practitioners</i> , 2006, 2, 665-672.	0.8	2
9	Current Awareness in Hematological Oncology. <i>Hematological Oncology</i> , 2006, 24, 89-96.	1.7	0
10	Bortezomib for multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1337-1346.	1.8	12
11	Haematology. <i>Journal of the Royal Army Medical Corps</i> , 2006, 152, 250-265.	0.8	0
12	Management of paraproteinaemia. <i>Postgraduate Medical Journal</i> , 2007, 83, 217-223.	1.8	36
13	Melphalan and its role in the management of patients with multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 945-957.	2.4	43
14	Bone marrow trephine combined with immunohistochemistry is superior to bone marrow aspirate in follow-up of myeloma patients. <i>Journal of Clinical Pathology</i> , 2007, 61, 213-216.	2.0	37
15	Multiple myeloma: causes and consequences of delay in diagnosis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2007, 100, 635-640.	0.5	124
16	To the Editor: In reply to Nakano et al. <i>Clin Chem Lab Med</i> 2006;44(5):522-532. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 264-5; author reply 266-7.	2.3	3
17	To the Editor: Author reply; Nakano et al. <i>Clin Chem Lab Med</i> 2006;44(5):522-532. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, .	2.3	0
18	The serum-free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias. <i>Blood</i> , 2007, 109, 3611-3612.	1.4	28
19	Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. <i>Blood</i> , 2007, 110, 3291-3300.	1.4	133

#	ARTICLE	IF	CITATIONS
20	Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clinica Chimica Acta, 2007, 376, 30-36.	1.1	89
21	Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry. Human Pathology, 2007, 38, 1779-1787.	2.0	55
22	Treatment Strategies in Elderly Patients with Multiple Myeloma. Drugs and Aging, 2007, 24, 829-850.	2.7	4
24	Gamopatas monoclonais: critérios diagnósticos e diagnósticos diferenciais. Revista Brasileira De Hematologia E Hemoterapia, 2007, 29, .	0.7	6
25	O transplante alogênico de células-tronco hematopoiéticas no tratamento do Mieloma Múltiplo. Revista Brasileira De Hematologia E Hemoterapia, 2007, 29, .	0.7	0
26	Tratamento do Mieloma Múltiplo recidivado. Revista Brasileira De Hematologia E Hemoterapia, 2007, 29, .	0.7	0
27	Multiple myeloma: understanding the impact of the disease. Cancer Nursing Practice, 2007, 6, 25-28.	0.0	7
28	Mieloma Múltiplo e insuficiência renal. Revista Brasileira De Hematologia E Hemoterapia, 2007, 29, .	0.7	1
29	Modified conditioning regimen usulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma. Chinese Medical Journal, 2007, 120, 463-468.	2.3	8
30	Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease¹. British Journal of Haematology, 2007, 138, 676-686.	2.5	81
31	Immunodeficiency and immunotherapy in multiple myeloma. British Journal of Haematology, 2007, 138, 563-579.	2.5	297
32	Outreach monitoring service for patients with indolent B-cell and plasma cell disorders: a UK experience. British Journal of Haematology, 2007, 139, 845-848.	2.5	11
33	Access to expensive drugs in the NHS: myths and realities for cancer patients. International Journal of Clinical Practice, 2007, 61, 2126-2129.	1.7	3
34	Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model. Experimental Hematology, 2007, 35, 1839-1846.	0.4	47
35	Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma. European Journal of Haematology, 2007, 79, 69-71.	2.2	31
36	Haematological anticancer drugs in Europe: any added value at the time of approval?. European Journal of Clinical Pharmacology, 2007, 63, 713-719.	1.9	17
37	Pneumococcal meningitis: a fatal complication of myeloma. Annals of Hematology, 2007, 86, 381-383.	1.8	2
38	Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 195-209.	4.9	33

#	ARTICLE	IF	CITATIONS
39	Percutaneous vertebroplasty at C2: case report of a patient with multiple myeloma and a literature review. <i>European Spine Journal</i> , 2007, 16, 242-249.	2.2	45
40	Pulmonary embolism in a patient with multiple myeloma receiving thalidomide+dexamethasone therapy. <i>International Journal of Hematology</i> , 2008, 87, 542-544.	1.6	2
41	Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. <i>Cancer</i> , 2008, 112, 129-135.	4.1	40
42	In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies. <i>Cancer</i> , 2008, 112, 1096-1105.	4.1	63
43	Increased acquired activated protein C resistance in unselected patients with hematological malignancies. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1482-1487.	3.8	29
44	Consensus guidelines for "rainy day" autologous stem cell harvests in New South Wales. <i>Internal Medicine Journal</i> , 2008, 38, 229-234.	0.8	5
45	Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. <i>British Journal of Haematology</i> , 2008, 141, 41-51.	2.5	118
46	The evolving use of serum free light chain assays in haematology. <i>British Journal of Haematology</i> , 2008, 141, 413-422.	2.5	86
47	Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder. <i>British Journal of Haematology</i> , 2008, 143, 496-502.	2.5	12
48	Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2008, 81, 380-383.	2.2	32
49	Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies. <i>Oral Oncology</i> , 2008, 44, 857-869.	1.5	227
50	Health technology assessment of magnetic resonance imaging of the spine and bone marrow. <i>European Journal of Radiology</i> , 2008, 65, 201-210.	2.6	3
51	Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: A 5-year retrospective analysis. <i>Clinical Therapeutics</i> , 2008, 30, 1704-1713.	2.5	19
53	Transcriptional regulation of autocrine IL-6 expression in multiple myeloma cells. <i>Cellular Signalling</i> , 2008, 20, 1489-1496.	3.6	39
54	¹⁸ F-FDG PET/CT, ^{99m} Tc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma. <i>Journal of Nuclear Medicine</i> , 2008, 49, 195-200.	5.0	155
55	Quantitation of Serum Free Light Chains in Combination with Protein Electrophoresis and Clinical Information for Diagnosing Multiple Myeloma in a General Hospital Population. <i>Clinical Chemistry</i> , 2008, 54, 1823-1830.	3.2	53
56	Current Trends in Multiple Myeloma Management. <i>Journal of International Medical Research</i> , 2008, 36, 371-386.	1.0	5
57	The effect of azacitidine on interleukin-6 signaling and nuclear factor- κ B activation and its in vitro and in vivo activity against multiple myeloma. <i>Haematologica</i> , 2008, 93, 860-869.	3.5	43

#	ARTICLE	IF	CITATIONS
58	Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. <i>Blood</i> , 2008, 111, 3155-3162.	1.4	171
59	Hypercoagulability in patients with haematological neoplasia: No apparent initiation by tissue factor. <i>Thrombosis and Haemostasis</i> , 2008, 99, 1040-1048.	3.4	43
61	Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case. <i>Haematologica</i> , 2009, 94, 1024-1028.	3.5	47
62	Quantitation of Serum Monoclonal Proteins: Relationship between Agarose Gel Electrophoresis and Immunonephelometry. <i>Clinical Chemistry</i> , 2009, 55, 1523-1529.	3.2	62
63	Bone Marrow. , 2009, , 1536-1593.		0
64	Screening for M-proteinemia: serum protein electrophoresis and free light chains compared. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 1507-11.	2.3	5
65	Quantitation of serum free light chains does not compensate for serum immunofixation only when screening for monoclonal gammopathies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 1109-15.	2.3	8
66	Fluorescent<i>in situ</i>hybridization studies in multiple myeloma. <i>Hematology</i> , 2009, 14, 90-94.	1.5	22
67	Multiple Myeloma in Chronic Kidney Disease. <i>Nephron Clinical Practice</i> , 2009, 111, c7-c11.	2.3	12
68	Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2009, 15, 714-722.	7.0	27
69	Utility of Serum Free Light Chain Analysis When Screening for Lymphoproliferative Disorders. <i>Laboratory Medicine</i> , 2009, 40, 325-329.	1.2	13
70	Utility of CD56 Immunohistochemical Studies in Follow-up of Plasma Cell Myeloma. <i>American Journal of Clinical Pathology</i> , 2009, 132, 60-66.	0.7	30
71	Multiple myeloma and paraproteinaemia. <i>Medicine</i> , 2009, 37, 212-216.	0.4	0
72	Healthâ€related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations. <i>European Journal of Haematology</i> , 2009, 83, 279-289.	2.2	46
73	Management of hematological malignancies during pregnancy. <i>American Journal of Hematology</i> , 2009, 84, 830-841.	4.1	90
74	Multiple myeloma presenting with spinal cord compression during pregnancy. <i>Annals of Hematology</i> , 2009, 88, 181-182.	1.8	25
75	UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected Mâ€proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). <i>British Journal of Haematology</i> , 2009, 147, 22-42.	2.5	116
76	Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. <i>Leukemia</i> , 2009, 23, 162-169.	7.2	69

#	ARTICLE	IF	CITATIONS
77	International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. <i>Leukemia</i> , 2009, 23, 1716-1730.	7.2	136
78	Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. <i>Internal Medicine Journal</i> , 2009, 39, 304-316.	0.8	44
79	United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma. <i>International Journal of Laboratory Hematology</i> , 2009, 31, 119-131.	1.3	1
80	Long-term cryopreservation of autologous stem cell grafts: a clinical and experimental study of hematopoietic and immunocompetent cells. <i>Transfusion</i> , 2009, 49, 1709-1719.	1.6	42
81	Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. <i>Blood Reviews</i> , 2009, 23, 87-93.	5.7	35
82	Imaging patients with myeloma. <i>Clinical Radiology</i> , 2009, 64, 1-11.	1.1	51
83	Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 812-816.	2.0	68
84	Gaucher disease and monoclonal gammopathy: A report of 17 cases and impact of therapy. <i>Blood Cells, Molecules, and Diseases</i> , 2009, 43, 138-139.	1.4	25
85	Serum tumour markers: how to order and interpret them. <i>BMJ, The</i> , 2009, 339, b3527-b3527.	6.0	85
86	Treatment of Multiple Myeloma: A Comprehensive Review. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 278-288.	1.4	135
87	Serum free light chain assessment in monoclonal gammopathy and kidney disease. <i>Nature Reviews Nephrology</i> , 2009, 5, 621-628.	9.6	56
88	Extramedullary plasmacytoma of the pancreas as an uncommon cause of obstructive jaundice: a case report. <i>Journal of Medical Case Reports</i> , 2009, 3, 8785.	0.8	18
89	Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure. <i>Journal of Clinical Oncology</i> , 2009, 27, 1788-1793.	1.6	315
90	Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2009, 360, 2645-2654.	27.0	168
91	Light Chains: Heavy Burden in Kidney Transplantation. <i>Transplantation</i> , 2009, 87, 947-952.	1.0	13
93	Nasopharyngeal amyloidosis: an unusual cause for epistaxis. <i>Journal of Laryngology and Otology</i> , 2010, 124, 209-212.	0.8	6
94	THE BELGIAN 2010 CONSENSUS RECOMMENDATIONS FOR THE TREATMENT OF MULTIPLE MYELOMA. <i>Acta Clinica Belgica</i> , 2010, 65, 252-264.	1.2	0
95	Determination of intrarenal resistance index (RI) in patients with multiple myeloma. <i>European Journal of Medical Research</i> , 2010, 15, 210-3.	2.2	2

#	ARTICLE	IF	CITATIONS
96	Somatostatin receptor scintigraphy might be useful for detecting skeleton abnormalities in patients with multiple myeloma and plasmacytoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 124-130.	6.4	24
97	A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. <i>Annals of Hematology</i> , 2010, 89, 185-190.	1.8	99
98	Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. <i>Annals of Hematology</i> , 2010, 89, 803-811.	1.8	32
99	Multiple myeloma: management of adverse events. <i>Medical Oncology</i> , 2010, 27, 646-653.	2.5	21
100	Management of disease- and treatment-related complications in patients with multiple myeloma. <i>Medical Oncology</i> , 2010, 27, 43-52.	2.5	25
101	Effect of wild type PTEN gene on proliferation and invasion of multiple myeloma. <i>International Journal of Hematology</i> , 2010, 92, 83-94.	1.6	17
102	Trends in the incidence and survival of multiple myeloma in South East England 1985-2004. <i>BMC Cancer</i> , 2010, 10, 74.	2.6	20
103	Reduced nutritional status among multiple myeloma patients during treatment with high-dose chemotherapy and autologous stem cell support. <i>Clinical Nutrition</i> , 2010, 29, 488-491.	5.0	12
104	<i>p53</i> deletion may drive the clinical evolution and treatment response in multiple myeloma. <i>European Journal of Haematology</i> , 2010, 84, 359-361.	2.2	47
105	Bone morphogenetic proteins and receptors are over-expressed in bone-marrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes. <i>Leukemia Research</i> , 2010, 34, 742-751.	0.8	26
106	EVITA: a tool for the early EVALuation of pharmaceutical Innovations with regard to Therapeutic Advantage. <i>BMC Clinical Pharmacology</i> , 2010, 10, 5.	2.5	12
107	Aberrant expression of the neuronal transcription factor <i>FOXP2</i> in neoplastic plasma cells. <i>British Journal of Haematology</i> , 2010, 149, 221-230.	2.5	34
108	Detecting methylation patterns of <i>p16</i> , <i>MGMT</i> , <i>DAPK</i> and <i>E-cadherin</i> genes in multiple myeloma patients. <i>International Journal of Laboratory Hematology</i> , 2010, 32, 142-149.	1.3	23
109	The additional role of bone marrow particle sections (â€˜clot sectionsâ€™™) in confirming marrow involvement by multiple myeloma: a single centre study. <i>International Journal of Laboratory Hematology</i> , 2010, 32, e179-80.	1.3	4
110	Soluble syndecan-1 at diagnosis and during follow up of multiple myeloma: a single institution study. <i>The Korean Journal of Hematology</i> , 2010, 45, 115.	0.7	21
111	Multiple myeloma. <i>Cancer Imaging</i> , 2010, 10, 20-31.	2.8	29
112	Induction chemotherapy before autologous stem cell transplantation for symptomatic plasma cell myeloma – does it matter?. <i>Clinical Pharmacology: Advances and Applications</i> , 2010, 2, 71.	1.2	1
113	Lily Robinson and Ready, on the Set Go. <i>Clinical Chemistry</i> , 2010, 56, 1201-1202.	3.2	0

#	ARTICLE	IF	CITATIONS
114	Estimation of Daily Proteinuria in Patients with Multiple Myeloma by Using the Protein-to-Creatinine Ratio in Random Urine Samples. <i>Acta Haematologica</i> , 2010, 123, 226-229.	1.4	5
115	Definitive diagnosis of multiple myeloma from rib specimens resected at thoracotomy in a patient with lung cancer. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2010, 10, 1051-1053.	1.1	5
116	Myeloma and the Kidney. , 2010, , 761-769.		2
117	Current Concepts in the Evaluation of Multiple Myeloma with MR Imaging and FDG PET/CT. <i>Radiographics</i> , 2010, 30, 127-142.	3.3	140
118	Pain management in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 415-425.	2.4	26
119	Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 419-426.	0.7	107
120	What is Your Guess? Detecting Only Light Chains, Now What?. <i>Clinical Chemistry</i> , 2010, 56, 1368-1368.	3.2	1
121	Combination of Intensive Chemotherapy and Anticancer Vaccines in the Treatment of Human Malignancies: The Hematological Experience. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-15.	3.0	23
122	Improved Survival for Multiple Myeloma in Denmark Based on Autologous Stem Cell Transplantation and Novel Drug Therapy in Collaborative Trials: Analysis of Accrual, Prognostic Variables, Selection Bias, and Clinical Behavior on Survival in More Than 1200 Patients in Trials of the Nordic Myeloma Study Group. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 290-296.	0.4	2
123	Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance. <i>Human Pathology</i> , 2010, 41, 1702-1710.	2.0	31
125	Bisphosphonate-related osteonecrosis of the jaw in cancer patients: Implications for nurses. <i>European Journal of Oncology Nursing</i> , 2010, 14, 205-210.	2.1	7
126	Presentation and risk stratification “improving prognosis for patients with multiple myeloma. <i>Cancer Treatment Reviews</i> , 2010, 36, S12-S17.	7.7	17
127	Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. <i>Leukemia and Lymphoma</i> , 2010, 51, 1424-1443.	1.3	49
128	Trends in the survival of patients diagnosed with malignant neoplasms of lymphoid, haematopoietic, and related tissue in the Nordic countries 1964–2003 followed up to the end of 2006. <i>Acta Oncologica</i> , 2010, 49, 694-712.	1.8	46
129	Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. <i>Blood</i> , 2011, 117, 4701-4705.	1.4	377
130	Improved Monitoring of Differences in Serial Laboratory Results. <i>Clinical Chemistry</i> , 2011, 57, 1635-1637.	3.2	24
131	85-Year-Old Man With Epistaxis. <i>Mayo Clinic Proceedings</i> , 2011, 86, 344-347.	3.0	0
132	Review of Physiologic and Pathophysiologic Sources of Fluorodeoxyglucose Uptake in the Chest Wall on PET. <i>PET Clinics</i> , 2011, 6, 339-364.	3.0	6

#	ARTICLE	IF	CITATIONS
133	Fractures in the Elderly. , 2011, , .		1
134	Magnesium to Myxoma. , 0, , 250-283.		0
135	Multiple Myeloma Presenting as Acute Renal Failure. Baylor University Medical Center Proceedings, 2011, 24, 302-305.	0.5	5
136	Transfer of influenza vaccineâ€“primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. Blood, 2011, 117, 63-71.	1.4	41
137	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood, 2011, 117, 6063-6073.	1.4	282
138	Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood, 2011, 118, 4086-4092.	1.4	173
139	Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study. Journal of Clinical Pharmacy and Therapeutics, 2011, 36, 19-26.	1.5	26
140	Guidelines for the diagnosis and management of multiple myeloma 2011. British Journal of Haematology, 2011, 154, 32-75.	2.5	252
141	Healthcare costs of multiple myeloma: an Italian study. European Journal of Cancer Care, 2011, 20, 330-336.	1.5	15
142	Multiple myeloma and pregnancy: a case report and literature review. Archives of Gynecology and Obstetrics, 2011, 284, 945-950.	1.7	11
143	Quality assessment, standardization. Clinical Chemistry and Laboratory Medicine, 2011, 49, .	2.3	1
144	Long-Term Biological Variation of Serum Protein Electrophoresis M-Spike, Urine M-Spike, and Monoclonal Serum Free Light Chain Quantification: Implications for Monitoring Monoclonal Gammopathies. Clinical Chemistry, 2011, 57, 1687-1692.	3.2	67
145	The outcome of high-dose chemotherapy and auto-SCT in patients with multiple myeloma: a UK/Ireland and European benchmarking comparative analysis. Bone Marrow Transplantation, 2011, 46, 1210-1218.	2.4	7
146	The Value of Serum Immunoglobulin Free Light Chain Assessment in Patients with Monoclonal Gammopathies and Acute Renal Failure. Turkish Journal of Haematology, 2012, 29, 385-391.	0.2	2
147	Recommendations for standardized reporting of protein electrophoresis in Australia and New Zealand. Annals of Clinical Biochemistry, 2012, 49, 242-256.	1.6	71
148	Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program. Expert Opinion on Biological Therapy, 2012, 12, 1449-1462.	3.1	18
149	Expression levels of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and focal adhesion kinase in patients with multiple myeloma and their relationship to clinical stage and extramedullary infiltration. Leukemia and Lymphoma, 2012, 53, 1162-1168.	1.3	23
150	Metabolic Tumor Volume Assessed by ¹⁸ F-FDG PET/CT for the Prediction of Outcome in Patients with Multiple Myeloma. Journal of Nuclear Medicine, 2012, 53, 1829-1835.	5.0	157

#	ARTICLE	IF	CITATIONS
151	Detection and quantification of M-proteinemia: comparison of various methods for serum protein electrophoresis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 77-80.	2.3	5
152	Proteinuria in the elderly: evaluation and management. <i>International Urology and Nephrology</i> , 2012, 44, 1745-1751.	1.4	17
153	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego na rok 2012. <i>Acta Haematologica Polonica</i> , 2012, 43, 7-47.	0.3	5
154	Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience. <i>Leukemia and Lymphoma</i> , 2012, 53, 1714-1721.	1.3	29
155	Treatment of Metastatic Spinal Cord Compression: cepto Review and Clinical Recommendations. <i>Current Oncology</i> , 2012, 19, 478-490.	2.2	45
156	Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents. <i>Hematological Oncology</i> , 2012, 30, 156-162.	1.7	10
157	Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) imaging of multiple myeloma: initial clinical efficiency results. <i>European Radiology</i> , 2012, 22, 1114-1121.	4.5	26
158	Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. <i>European Journal of Haematology</i> , 2012, 88, 485-496.	2.2	42
159	Radical surgical treatment of bisphosphonate related osteonecrosis of the jaw. <i>Australian Dental Journal</i> , 2012, 57, 227-230.	1.5	11
160	Assessment of the diagnostic performances of IgA heavy and light chain pairs in patients with IgA monoclonal gammopathy. <i>Clinical Biochemistry</i> , 2013, 46, 79-84.	1.9	7
161	Role of 18F-fluoride PET/CT in the assessment of multiple myeloma: initial experience. <i>Annals of Nuclear Medicine</i> , 2013, 27, 78-83.	2.2	25
162	Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 619-634.	4.1	17
163	Clinical and Organizational Factors in the Initial Evaluation of Patients With Lung Cancer. <i>Chest</i> , 2013, 143, e121S-e141S.	0.8	148
164	MRI for Response Assessment In Oncologic Bone Marrow Lesions. <i>Medical Radiology</i> , 2013, , 121-143.	0.1	1
165	Radiation Therapy for Secondary Cutaneous Plasmacytomas. <i>Case Reports in Hematology</i> , 2013, 2013, 1-5.	0.4	3
166	Cyclin D1 expression in multiple myeloma by immunohistochemistry: Case series of 14 patients and literature review. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2013, 34, 283-291.	0.2	12
167	Utilisation of s<scp>FLC</scp> assays â€“ how well do we comply with guidelines?. <i>International Journal of Laboratory Hematology</i> , 2013, 35, 200-210.	1.3	3
168	Cost of Illness in Patients with Multiple Myeloma in Italy: The CoMiM Study. <i>Tumori</i> , 2013, 99, e193-e202.	1.1	14

#	ARTICLE	IF	CITATIONS
169	Multiple myeloma: optimal management and long-term disease control. Blood and Lymphatic Cancer: Targets and Therapy, 2014, , 121.	2.7	0
170	Diagnostic et suivi d'un d'œficit de'immunitœ humorale. , 2014, , 127-137.		0
171	Diagnostic d'une dysglobulinœmie. , 2014, , 139-152.		0
172	68Ga-DOTANOC Somatostatin Receptor PET-CT Imaging in Multiple Myeloma. Clinical Nuclear Medicine, 2014, 39, 374-375.	1.3	9
173	Long-Term Results in Multiple Myeloma After High-Dose Melphalan and Autologous Transplantation According to Response Categories in the Era of Old Drugs. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 148-154.	0.4	13
174	18F-FDG PET Increases Visibility of Bone Lesions in Relapsed Multiple Myeloma. Clinical Nuclear Medicine, 2015, 40, 291-296.	1.3	8
175	Monitoring IgA Multiple Myeloma: Immunoglobulin Heavy/Light Chain Assays. Clinical Chemistry, 2015, 61, 360-367.	3.2	57
176	Pre-treatment staging of multiple myeloma patients: comparison of whole-body diffusion weighted imaging with whole-body T1-weighted contrast-enhanced imaging. Acta Radiologica, 2015, 56, 733-738.	1.1	26
177	Zalecenia Polskiej Grupy Szpiczakowej dotyczœ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskracji plazmocytowych na rok 2015. Acta Haematologica Polonica, 2015, 46, 159-211.	0.3	0
178	Strategy for Detecting and Following Monoclonal Gammopathies. , 0, , 112-124.		4
179	The Prevalence and Management of Multiple Myeloma-Induced Kidney Disease in China. Kidney Diseases (Basel, Switzerland), 2016, 1, 235-240.	2.5	10
180	Combined use of free light chain and heavy/light chain ratios allow diagnosis and monitoring of patients with monoclonal gammopathies: Experience of a single institute, with three exemplar case reports. Oncology Letters, 2016, 12, 2363-2370.	1.8	4
181	Randomized phase III trial of consolidation therapy with bortezomib+œlenalidomide+œDexamethasone (VRd) vs bortezomib+œdexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen. Blood Cancer Journal, 2016, 6, e448-e448.	6.2	13
182	Secondary immunodeficiency in lymphoproliferative malignancies. Hematological Oncology, 2016, 34, 121-132.	1.7	68
183	Amyloidosis presenting as macroglossia and restricted tongue movement. Dental Update, 2016, 43, 641-647.	0.2	5
184	Challenges of measuring monoclonal proteins in serum. Clinical Chemistry and Laboratory Medicine, 2016, 54, 947-61.	2.3	55
185	Solitary Extramedullary Plasmacytoma of the Maxillary Sinus, Progressing to Smoldering Multiple Myeloma with Multifocal Skeletal Involvement, which Resolved Completely Following Chemotherapy Alone. Journal of Maxillofacial and Oral Surgery, 2016, 15, 229-239.	1.4	6
186	How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?. Critical Reviews in Oncology/Hematology, 2017, 112, 153-170.	4.4	37

#	ARTICLE	IF	CITATIONS
187	Outcome and survival of myeloma patients diagnosed 2008–2015. Real-world data on 4904 patients from the Swedish Myeloma Registry. <i>Haematologica</i> , 2018, 103, 506-513.	3.5	103
188	Underutilization of guideline-recommended supportive care among older adults with multiple myeloma in the United States. <i>Cancer</i> , 2019, 125, 4084-4095.	4.1	10
189	Multiple myeloma of young adult presented with paraplegia, rare case report in Saudi Arabia. <i>BJR case Reports</i> , 2019, 5, 20190008.	0.2	0
190	Myeloma Cell Detection in Bone Marrow Aspiration Using Microscopic Images. , 2019, , .		8
192	Rapid in-situ hybridization and immunohistochemistry: a pilot comparative study of two rapid diagnostic techniques for establishing monoclonality in plasma cell dyscrasias. <i>Medical Journal Armed Forces India</i> , 2020, 76, 103-108.	0.8	0
193	Measurement of Monoclonal Immunoglobulin Protein Concentration in Serum Protein Electrophoresis: Comparison of Automated vs Manual/Human Readings. <i>Laboratory Medicine</i> , 2020, 51, 252-258.	1.2	10
194	Visual and volumetric parameters by 18F-FDG-PET/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 127-135.	1.8	18
195	Deep Learning Based Approach for Multiple Myeloma Detection. , 2020, , .		17
196	Theory-driven development of a medication adherence intervention delivered by eHealth and transplant team in allogeneic stem cell transplantation: the SMILE implementation science project. <i>BMC Health Services Research</i> , 2020, 20, 827.	2.2	24
197	Recommendations on the management of multiple myeloma in 2020. <i>Acta Clinica Belgica</i> , 2020, , 1-17.	1.2	1
198	No decrease in fracture risk despite 15+ years of treatment evolution for multiple myeloma patients: A Danish nationwide case-control study. <i>Bone</i> , 2020, 134, 115299.	2.9	3
199	Burden of Treatment-Induced Peripheral Neuropathy in Patients with Multiple Myeloma in Sweden. <i>Acta Haematologica</i> , 2021, 144, 519-527.	1.4	0
200	Pathologic Fractures. , 2011, , 43-53.		3
201	Monoclonal gammopathies. , 2013, , 975-986.		3
202	Multiple myeloma presenting with bilateral ankle pain (microangiopathy) and complicated by streptococcal meningitis and <i>Pneumocystis carinii</i> pneumonia. <i>BMJ Case Reports</i> , 2017, 2017, bcr2016217289.	0.5	2
203	Inherited Polymorphisms in Hyaluronan Synthase 1 Predict Risk of Systemic B-Cell Malignancies but Not of Breast Cancer. <i>PLoS ONE</i> , 2014, 9, e100691.	2.5	7
204	Plerixafor in poor stem cell mobilizers: the Belgian Compassionate Use Program. <i>Acta Clinica Belgica</i> , 2011, 66, 200-4.	1.2	5
205	Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. <i>Core Evidence</i> , 2010, 4, 215.	4.7	18

#	ARTICLE	IF	CITATIONS
206	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskracji plazmocytowych na rok 2018/2019. Acta Haematologica Polonica, 2018, 49, 157-206.	0.3	4
207	Gastrointestinal bleeding as initial presentation of extramedullary plasma cell neoplasms: A case report and review of the literature. World Journal of Gastrointestinal Endoscopy, 2019, 11, 308-321.	1.2	9
208	Laboratory medicine in primary care: Paraprotein management. BMJ, The, 2007, 334, 0703101.	6.0	0
210	Risk assessment for multiple myeloma: preliminary results of the brazilian myeloma study group. Revista Brasileira De Hematologia E Hemoterapia, 0, 30, .	0.7	1
211	Hematologic Disorders. , 2009, , 571-612.		0
213	Multiple Myeloma and Plasmacytoma. , 2010, , 599-604.		0
215	Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations. Swiss Medical Weekly, 2010, 140, w13054.	1.6	4
216	Multiple Myeloma Surveillance Counterpoint: Australia. , 2013, , 493-500.		0
217	Multiple Myeloma Surveillance Counterpoint: Canada. , 2013, , 503-509.		0
218	A detailed approach on multiple myeloma and its treatment. International Journal of Basic and Clinical Pharmacology, 2013, 2, 671.	0.1	0
219	Pancytopenia in Multiple Myeloma- An Enigma: Our Experience from Tertiary Care Hospital. Journal of Clinical and Diagnostic Research JCDR, 2015, 9, EC04-6.	0.8	5
220	Acute complications in multiple myeloma. Sanamed, 2017, 12, 115-119.	0.2	1
221	Clinical case of observation of a patient with multiple myeloma. KliniÄeskaÄ StomatologiÄ, 2019, , 81-83.	0.2	0
222	Gastrointestinal bleeding as initial presentation of extramedullary plasma cell neoplasms: A case report and review of the literature. World Journal of Gastrointestinal Endoscopy, 2019, 11, 309-322.	1.2	1
223	Reporting of quantitative protein electrophoresis in Australia and New Zealand: a call for standardisation. Clinical Biochemist Reviews, 2009, 30, 141-51.	3.3	7
224	Bortezomib: the evidence of its clinical impact in multiple myeloma. Core Evidence, 2006, 1, 265-77.	4.7	1
225	Clinical features and diagnosis of multiple myeloma: a population-based cohort study in primary care. BMJ Open, 2021, 11, e052759.	1.9	0
226	Exploring Stem Cell Transplanted Patientsâ€™ Perspectives on Medication Self-Management and Electronic Monitoring Devices Measuring Medication Adherence: A Qualitative Sub-Study of the Swiss SMILe Implementation Science Project. Patient Preference and Adherence, 2022, Volume 16, 11-22.	1.8	8

#	ARTICLE	IF	CITATIONS
227	Learning to Detect Monoclonal Protein in Electrophoresis Images. , 2021, , .		4
228	Clinical features and diagnosis of multiple myeloma: a population-based cohort study in primary care. BMJ Open, 2021, 11, e052759.	1.9	9
229	Cost of illness in patients with multiple myeloma in Italy: the CoMiM study. Tumori, 2013, 99, e193-202.	1.1	8
230	Osteolytic Lesion of the Maxilla in an Undiagnosed Multiple Myeloma Patient Identified Incidentally by Cone Beam Computed Tomography. American Journal of Case Reports, 0, 23, .	0.8	1
231	Diffusion-weighted imaging (DWI) in diagnosis, staging, and treatment response assessment of multiple myeloma: a systematic review and meta-analysis. Skeletal Radiology, 2023, 52, 565-583.	2.0	5
233	Automated Bone Fracture Detection Using Convolutional Neural Network. Journal of Physics: Conference Series, 2023, 2471, 012003.	0.4	1
234	Patient-reported symptoms and diagnostic journey in Multiple Myeloma. Frontiers in Oncology, 0, 13, .	2.8	0